SUNGJIN PARK

Prof. SUNGJIN PARK

Gachon University Gil Medical Center, Incheon, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2020 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
JKJin-Hee Kim
Jin-Hee Kim
SPSUNGJIN PARK
SUNGJIN PARK
SLSeung Mook Lim
Seung Mook Lim
HEHyo Jin Eom
Hyo Jin Eom
CBCurt Balch
Curt Balch
YKYon Hui Kim
Yon Hui Kim

Verified
Journal Article
Open access
PDF file
APAron Park
Aron Park
SCSeung Joon Choi
Seung Joon Choi
SPSUNGJIN PARK
SUNGJIN PARK
SKSEONG MIN KIM
SEONG MIN KIM
HLHye Eun Lee
Hye Eun Lee
Dae Ho LeeDae Ho Lee
Dae Ho Lee
We found several blood biomarkers through computational secretome analyses, including aldo-keto reductase family 1 member B10 (AKR1B10), which reflected the progression of nonalcoholic fatty liver disease (NAFLD). After confirming that hepatic AKR1B10 reflected the progression of NAFLD in a subgroup with NAFLD, we evaluated the diagnostic accuracy of plasma AKR1B10 and other biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis in replication cohort. We enrolled healthy control subjects and patients with biopsy-proven NAFLD (n = 102) and evaluated the performance of various diagnostic markers. Plasma AKR1B10 performed well in the diagnosis of NASH with an area under the receiver operating characteristic (AUROC) curve of 0.834 and a cutoff value of 1078.2 pg/mL, as well as advanced fibrosis (AUROC curve value of 0.914 and cutoff level 1078.2 pg/mL), with further improvement in combination with C3. When we monitored a subgroup of obese patients who underwent bariatric surgery (n = 35), plasma AKR1B10 decreased dramatically, and 40.0% of patients with NASH at baseline showed a decrease in plasma AKR1B10 levels to below the cutoff level after the surgery. In an independent validation study, we proved that plasma AKR1B10 was a specific biomarker of NAFLD progression across varying degrees of renal dysfunction. Despite perfect correlation between plasma and serum levels of AKR1B10 in paired sample analysis, its serum level was 1.4-fold higher than that in plasma. Plasma AKR1B10 alone and in combination with C3 could be a useful noninvasive biomarker for the diagnosis of NASH and hepatic fibrosis.

24 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SHSanghoon Han
Sanghoon Han
SPSUNGJIN PARK
SUNGJIN PARK
JAJungsuk An
Jungsuk An
JYJun-Young Yang
Jun-Young Yang
JCJun-Won Chung
Jun-Won Chung
JKJung Ho Kim
Jung Ho Kim
Human epidermal growth factor receptor 2 (HER2) is implicated in several cancers, including gastric cancer. However, limited data are available regarding its clinical significance in early gastric cancer (EGC). We evaluated the clinical significance of HER2 overexpression in patients with EGC. We retrospectively reviewed 727 patients who underwent surgical treatment for EGC between October 2010 and August 2017. HER2 expression was analysed in 680 EGC cases by immunohistochemistry and classified as negative (0 and 1+), equivocal (2+), or positive [overexpression (3+)]. Among patients with differentiated EGC, the number of patients with HER2 overexpression was not significantly different from that of HER2-negative patients in terms of age, sex, tumour size, location, gross type, depth of invasion, presence of lymphovascular invasion (LVI), and presence of lymph node metastasis (LNM). However, in patients with undifferentiated EGC, HER2 overexpression was significantly correlated with LVI and presence of LNM compared with HER2-negative patients. Multivariate analysis indicated HER2 overexpression as a good predictive marker of LNM in patients with undifferentiated EGC. HER2 expression is associated with LNM in undifferentiated EGC. Therefore, the importance of HER2 overexpression in EGC should not be overlooked, and further studies are needed to identify its clinical significance.

22 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MBMyeonghun Beak
Myeonghun Beak
SPSUNGJIN PARK
SUNGJIN PARK
JKJin-Hee Kim
Jin-Hee Kim
HEHyo Jin Eom
Hyo Jin Eom
HLHo-Yeon Lee
Ho-Yeon Lee
Seungyoon NamSeungyoon Nam
Seungyoon Nam
Ras homologous A (RHOA), a signal mediator and a GTPase, is known to be associated with the progression of gastric cancer (GC), which is the fourth most common cause of death in the world. Previously, we designed pharmacologically optimized inhibitors against RHOA, including JK-136 and JK-139. Based on this previous work, we performed lead optimization and designed novel RHOA inhibitors for greater anti-GC potency. Two of these compounds, JK-206 and JK-312, could successfully inhibit the viability and migration of GC cell lines. Furthermore, using transcriptomic analysis of GC cells treated with JK-206, we revealed that the inhibition of RHOA might be associated with the inhibition of the mitogenic pathway. Therefore, JK-206 treatment for RHOA inhibition may be a new therapeutic strategy for regulating GC proliferation and migration.

22 June 2022 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SPSUNGJIN PARK
SUNGJIN PARK
JAJungsuk An
Jungsuk An
SHSeung Yeon Ha
Seung Yeon Ha
Seungyoon NamSeungyoon Nam
Seungyoon Nam
JKJung Ho Kim
Jung Ho Kim

9 October 2019 in Genes
Verified
Journal Article
Open access
PDF file
SPSUNGJIN PARK
SUNGJIN PARK
SMSeongRyeol Moon
SeongRyeol Moon
KLKiyoung Lee
Kiyoung Lee
IPIe Byung Park
Ie Byung Park
DLDae Ho Lee
Dae Ho Lee
Seungyoon NamSeungyoon Nam
Seungyoon Nam
MicroRNAs (miRNAs) have been established as critical regulators of the pathogenesis of diabetes mellitus (DM), and diabetes microvascular complications (DMCs). However, manually curated databases for miRNAs, and DM (including DMCs) association studies, have yet to be established. Here, we constructed a user-friendly database, “miR2Diabetes,” equipped with a graphical web interface for simple browsing or searching manually curated annotations. The annotations in our database cover 14 DM and DMC phenotypes, involving 156 miRNAs, by browsing diverse sample origins (e.g., blood, kidney, liver, and other tissues). Additionally, we provide miRNA annotations for disease-model organisms (including rats and mice), of DM and DMCs, for the purpose of improving knowledge of the biological complexity of these pathologies. We assert that our database will be a comprehensive resource for miRNA biomarker studies, as well as for prioritizing miRNAs for functional validation, in DM and DMCs, with likely extension to other diseases.